Skip to content

US · PYXS · BIOTECHNOLOGY

Pyxis Oncology, Inc. (PYXS) intrinsic value and stock valuation

$1.81as of 2026-11-21 · Mkt cap 236.32M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pyxis Oncology, Inc. DCF and intrinsic value

InvestorsCraft values PYXS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PYXS’s statements →

Pyxis Oncology, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02118 pyxisoncology.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$13.9M
20192025
Net income
-$-79.62M
20192025
Free cash flow
-$-63.51M
20192025
Total equity
$53.4M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$13.9M$16.2M$0.00$0.00$0.00
Operating income-$-84.42M-$-89.46M-$-82.2M-$-123.48M-$-69.72M
Net income-$-79.62M-$-77.33M-$-73.79M-$-120.72M-$-75.97M
EPSd-$-1.28M-$-1.32M-$-1.85M-$-3.65M-$-2.36M
Operating cash flow-$-63.5M-$-57.67M-$-70.71M-$-89.33M-$-35.33M
Capital expenditure-$-10K-$-240K-$-6.73M-$-6.4M-$-540K
Free cash flow-$-63.51M-$-57.91M-$-77.44M-$-95.73M-$-35.87M
Total assets$91.5M$157.2M$173.7M$211.4M$280M
Total debt$18.7M$20.2M$21.3M$18.9M$170K
Net debt$3.25M$730K$11.7M-$-160.37M-$-274.57M
Total equity$53.4M$120.8M$125.7M$160.8M$261.3M
Cash and short-term investments$66.9M$126.9M$119.3M$179.3M$274.7M
Income statement
20252024202320222021
Revenue$13.9M$16.2M$0.00$0.00$0.00
Cost of revenue$2.39M$470K$0.00$0.00$0.00
Gross profit$11.5M$15.7M$0.00$0.00$0.00
Research and development expenses$73.7M$58.8M$49.6M$86.1M$51.1M
Selling, general and administrative expenses$22.2M$25.4M$32.6M$37.4M$18.7M
Other expenses$0.00$21M$0.00$0.00$0.00
Operating expenses$95.9M$105.1M$82.2M$123.5M$69.7M
Cost and expenses$98.3M$105.6M$82.2M$123.5M$69.7M
Interest income$3.61M$7.04M$6.63M$2.76M$20K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$4.51M$2.98M$1.93M$710K$650K
Ebitda-$-73.72M-$-65.51M-$-71.86M-$-120.01M-$-75.33M
Operating income-$-84.42M-$-89.46M-$-82.2M-$-123.48M-$-69.72M
Total other income/expenses, net$6.18M$9.96M$8.41M$2.76M-$-6.26M
Income before tax-$-78.23M-$-79.5M-$-73.79M-$-120.72M-$-75.97M
Income tax expense$1.39M-$-2.16M$0.00$0.00$0.00
Net income-$-79.62M-$-77.33M-$-73.79M-$-120.72M-$-75.97M
Weighted average shares outstanding$62.1M$58.5M$39.9M$33M$32.2M
Weighted average diluted shares outstanding$62.1M$58.5M$39.9M$33M$32.2M
Balance sheet
20252024202320222021
Cash and short-term investments$66.9M$126.9M$119.3M$179.3M$274.7M
Net receivables$700K$0.00$20K$600K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$72.1M$132.4M$124.6M$186.6M$278.7M
Property, plant and equipment, net$19.4M$22.1M$24.8M$24.8M$1.24M
Goodwill and intangible assets$0.00$2.6M$24.3M$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$19.4M$24.7M$49.1M$24.8M$1.35M
Total assets$91.5M$157.2M$173.7M$211.4M$280M
Accounts payable$10.9M$4.86M$3.9M$7.1M$12M
Short-term debt$1.69M$1.45M$1.23M$0.00$170K
Deferred revenue$0.00$0.00$7.66M$0.00$0.00
Total current liabilities$21.1M$17.7M$25.8M$31.6M$18.7M
Long-term debt$17M$18.8M$20.1M$18.9M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$17M$18.8M$22.3M$18.9M$0.00
Capital lease obligations$18.7M$20.2M$21.3M$18.9M$170K
Total liabilities$38.1M$36.4M$48M$50.6M$18.7M
Common stock$60K$60K$40K$30K$30K
Retained earnings-$-443.18M-$-363.56M-$-286.23M-$-212.44M-$-91.72M
Accumulated other comprehensive income (loss)$50K$170K$60K$0.00$0.00
Total equity$53.4M$120.8M$125.7M$160.8M$261.3M
Total investments$51.4M$107.5M$109.6M$0.00$0.00
Total debt$18.7M$20.2M$21.3M$18.9M$170K
Net debt$3.25M$730K$11.7M-$-160.37M-$-274.57M
Cash flow statement
20252024202320222021
Net income-$-79.62M-$-77.33M-$-73.79M-$-120.72M-$-75.97M
Depreciation and amortization$4.51M$2.98M$1.93M$710K$650K
Stock-based compensation$11.8M$13M$17M$15.8M$6.44M
Change in working capital$1.94M-$-11.82M-$-11.66M$4.5M$6.68M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$6.03M$1.2M-$-3.51M-$-8.33M$4.64M
Net cash provided by operating activities-$-63.5M-$-57.67M-$-70.71M-$-89.33M-$-35.33M
Investments in property, plant and equipment-$-10K-$-240K-$-6.73M-$-6.4M-$-540K
Acquisitions, net$0.00$0.00$6.66M$0.00-$-50K
Net cash used for investing activities$58.9M$8.15M-$-104.85M-$-6.4M-$-590K
Common stock issued$740K$59.1M$6.12M$0.00$152.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$590K$59.3M$5.93M$180K$304M
Net change in cash-$-4.05M$9.81M-$-169.63M-$-95.55M$268.1M
Cash at end of period$16.9M$21M$11.1M$180.8M$276.3M
Operating cash flow-$-63.5M-$-57.67M-$-70.71M-$-89.33M-$-35.33M
Capital expenditure-$-10K-$-240K-$-6.73M-$-6.4M-$-540K
Free cash flow-$-63.51M-$-57.91M-$-77.44M-$-95.73M-$-35.87M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pyxis Oncology, Inc.

        Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

        CEO
        Thomas Civik
        Employees
        56
        Beta
        1.31

        Explore

        Frequently asked questions

        What is the intrinsic value of Pyxis Oncology, Inc. (PYXS)?

        InvestorsCraft does not currently publish an intrinsic value for PYXS. How the IC value is calculated.

        Is PYXS undervalued?

        InvestorsCraft does not publish an undervaluation signal for PYXS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.